echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sansheng Guojian SSGJ-706 was approved by the FDA to enter Phase I-II clinical trials

    Sansheng Guojian SSGJ-706 was approved by the FDA to enter Phase I-II clinical trials

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 18th, Sansheng Guojian issued an announcement stating that the company's SSGJ-706 treatment of advanced solid tumors, relapsed or refractory lymphomas has been approved by the US FDA to enter Phase I/II clinical studies
    .

    SSGJ-706 is a recombinant bispecific antibody developed by Sansheng Guojian with independent intellectual property rights (bispecific antibody platform)
    .


    The antibody simultaneously binds to PD1 and another target closely related to tumor immunosuppressive function, thereby more effectively promoting T cell activation and proliferation, and further enhancing its tumor killing activity


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.